Isbell v. Baxter Healthcare, Corp.

273 F. Supp. 3d 965
CourtDistrict Court, N.D. Illinois
DecidedMarch 31, 2017
DocketNo. 15 C 7333
StatusPublished
Cited by5 cases

This text of 273 F. Supp. 3d 965 (Isbell v. Baxter Healthcare, Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Isbell v. Baxter Healthcare, Corp., 273 F. Supp. 3d 965 (N.D. Ill. 2017).

Opinion

MEMORANDUM OPINION AND ORDER

REBECCA R. PALLMEYER, United States District Judge

Plaintiff Debbie Isbell worked for Defendant Baxter Healthcare Corporation (“Baxter”) from 2007 to 2013; during the end of that time her job involved promoting Baxter’s products in other countries. Beginning in 2012, Isbell complained, about, among other things, the tendency of one of her coworkers, Blair Waite, to make comments about an erectile dysfunction drug, including references to the marketing campaign for the drug and a few inappropriate jokes. Isbell’s own performance drew criticism from her co-workers, as well. Waite began excluding Isbell from meetings (it is unclear exactly when that started), and in July 2013, Isbell renewed her complaints to Baxter HR and added that she was being retaliated against for her 2012 complaints. Isbell’s supervisor, Antoinette Gawin, terminated Isbell in August 2013, after receiving a variety of complaints from Isbell and about her. Isbell brought this action asserting retaliation under 42 U.S.C. § 2000e, et seq. for her internal complaints of purported harassment and retaliation. Baxter has moved for summary judgment, which the court grants for the reasons below.

BACKGROUND

. Baxter, headquartered in Deerfield, Illinois, makes and markets healthcare products. (Def. Baxter’s Local Rule 56.1 Statement of Undisputed Material Facts in Supp. of Summ. J. Mot. (“DSOF”) [24] ¶ 1.) Baxter hired Isbell,1 who had previous experience in the healthcare industry, in March 2007 as a Group Marketing Manager in its “cellular therapies” business (“CT”). (Id. at ¶ 3; Pl.’s Statement of Additional Facts in Resp. to Def. Baxter’s Mot. for Summ. J. (“PSOAF”) [33] ¶1.) Isbell’s responsibilities included, among other things, “conducting market research; ... working on regulatory issues; working on reimbursement issues; working on a Japan project; creating] contracts; participating in advisory boards; and attending medical meetings.” (Pl.’s Resp. to Def. Baxter’s Rule 56.1(a) Statement of Undisputed Facts in Supp. of Summ. J. Mot. (“PL’s Resp. to DSOF”) [38] ¶3.) Isbell had some disputes with her supervisor in the CT group, none of which are relevant here. (See id. at ¶¶ 4-6.)

In November 2011, Isbell transferred into Baxter’s Renal Division, where she became a Senior Manager for Market Access. (DSOF ¶ 9.) Market Access staff are “responsible for developing tools and products to help [business units for different countries] gain access to the health care [969]*969system for an existing business[.]” (Dep. of Bruce Culleton, Ex. D to PSOAF (“Culle-ton Dep.”) [36] 18:22-19:10.) One of Isbell’s primary responsibilities in this role was to create and maintain Baxter’s global value dossier (“GVD”), which was “intended to be a repository of information from which all the marketers and people in that function would pull information.” (Dep. of Antoinette Gawin, Ex. A to PSOAF (“Gawin Dep.”) [33-1] 82:16-83:1.) Isbell worked on other projects, as well. (See id.) When she began working in Market Access, Isbell reported to Gary Inglese, but after Inglese left Baxter at the end of 2012, Isbell began reporting to Antoinette Gawin. (DSOF ¶¶ 9, 12; see Gawin Dep. 4:3-6.) Before Inglese departed, he wrote Isbell’s 2012 performance review. (Dep. of Deborah Sarason, Ex.' F to PSOAF (“Isbell Dep”) [40]-[43] 172:19-174:9.) Isbell testified that Inglese had told her that her performance exceeded expectations, but when she received the review in early 2013, she found that Baxter rated her as “meets expectations.” (Id)

1. Isbell’s Internal Complaints at Baxter

A. 2012 Complaints to Inglese

Isbell’s complaints centered primarily on Blair Waite, a senior director of new product development at the time Isbell was terminated. (Dep. of Blair Waite, Ex. E to PSOAF (“Waite Dep.”) [37] 13:19-22.) Before he worked at ’ Baxter, Waite had worked at Eli Lilly Pharmaceuticals, where he helped develop the marketing campaign' for the erectile dysfunction drug Cialis. (DSOF ¶ 62.) Waite acknowledged that when he worked at Eli Lilly, a coworker had complained about a comment Waite had made about the physiological effects of Cialis, and that Waite received a verbal warning as a result. (Waite Dep. 69:12-71:6.)

Isbell testified that during, meetings, Waite “brought up Cialis and talked about Cialis and what he did and how he launched it and how successful it was and how.... he can bring that marketing expertise .... ” (Isbell Dep. 148:8-16.) Isbell also described two incidents where Waite and Inglese joked about Cialis and erectile dysfunction in her presence, in December 2011 and March 2012.2 (See id. -at 148:8-151:16.)

Isbell described one incident that occurred in December 2011, when she was in Waite’s office with Inglese and Waite. (Id. at 148:22-149:18.) Inglese and Waite spoke about Cialis and made “innuendos, like bantering back and forth about like, hey, you know, I might need some of that. Oh yeah. Oh yeah, I do too, and, it just, you know, it just was inappropriate.” (Id.) According to Isbell, Inglese said “I need some of that,” while Waite responded “oh, yeah, yeah, I bet you do.” (Id. at 149:19— 23.) Isbell recalled that these comments went on for “maybe a minute.” (Id. at 149:24-160:4.) On another occasion, in March 2012, Isbell was again in Waite’s office with Waite and Inglese, “talk[ing] about work streams and strategies for market access and where that fit into marketing work streams.” (Id. at 150:6-19.) Inglese again mentioned Cialis, and the same kind of banter went on, again for about a minute. (Id. at 150:20-151:8.)

[970]*970Isbell has identified only two occasions in which Waite joked about Cialis, though she testified that Waite did continue to discuss Cialis in meetings. Isbell .felt this was inappropriate, because it was repetitive, it “had nothing to do with what we were working on,” and she “didn’t really want to think about erectile dysfunction in [her] day-to-day work environment.” (Id. at 151:9-24.) Isbell does not explicitly say how many people were at these general meetings where Waite described his successful marketing efforts for Cialis, but she testified “if he did it once and said what a great marketer he was to the team of 40 people, that would have been sufficient, but it kept being brought up again and again and again.” (Id. at 152:1-11.) Waite denies that he made sexual jokes about Cialis at work, but acknowledged he may have done so outside of work. (Waite Dep, 43:8-44:18.) He admitted that he may have made what Isbell called “nonsexual” Cialis jokes in meetings; Waite’s example was that in a marketing meeting he might have said “hey, I’ve gone this far [in this meeting] and I haven’t made a single marketing reference to Cialis.” (Id. at 44:19-45:18.)

Isbell also complained that Waite kept “all this Cialis sales paraphernalia all over the place” in his office. (Isbell Dep. 145:11-22.) Specifically, there were six or seven items: five-inch long bathtubs bearing the Cialis logo (presumably an homage to the television ads depicting side-by-side bathtubs), and some Cialis brochures. (Id. at 146:15-147:9.) Isbell acknowledged that none of the Cialis promotional materials displayed genitalia, but she was uncomfortable seeing them in a professional situation (id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sanchez v. Catholic Bishop of Chi.
344 F. Supp. 3d 959 (E.D. Illinois, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
273 F. Supp. 3d 965, Counsel Stack Legal Research, https://law.counselstack.com/opinion/isbell-v-baxter-healthcare-corp-ilnd-2017.